Updated results from the phase II study of hyper-CVAD in combination with ofatumumab as frontline therapy for adults with CD20 positive (CD20+) acute lymphoblastic leukemia (ALL).

被引：0
|
作者：
Issa, Ghayas C.
Kantarjian, Hagop M.
Ravandi, Farhad
Thomas, Deborah A.
Khouri, Maria
Garcia-Manero, Guillermo
Garris, Rebecca S.
Cortes, Jorge E.
Short, Nicholas James
Sasaki, Koji
Schroeder, Heather M.
Kadia, Tapan M.
Verstovsek, Srdan
Daver, Naval Guastad
Jain, Nitin
Konopleva, Marina
O'Brien, Susan Mary
Jabbour, Elias
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.7042
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7042
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Phase II Study of Combination of hyperCVAD with Dasatinib in Frontline Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)
    Ravandi, Farhad
    Thomas, Deborah
    Kantarjian, Hagop
    Faderl, Stefan
    Koller, Charles
    Dara, Samuel
    Garris, Rebecca
    Kebriaei, Partow
    Borthakur, Gautam
    Wierda, William
    Burger, Jan
    Cortes, Jorge
    O'Brien, Susan
    BLOOD, 2008, 112 (11) : 1005 - 1005
  • [42] Long-term follow-up after frontline therapy with the Hyper-CVAD and imatinib mesylate regimen in adults with Philadelphia (Ph) positive acute lymphocytic leukemia (ALL)
    Thomas, Deborah A.
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Faderl, Stefan
    Garcia-Manero, Guillermo
    Wierda, William
    Ferrajoli, Alessandra
    Vertovsek, Srdan
    Jones, Dan
    Letvak, Laurie
    Champlin, Richard
    Cortes, Jorge
    O'Brien, Susan
    BLOOD, 2007, 110 (11) : 10A - 11A
  • [43] The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study
    Short, Nicholas
    Jabbour, Elias
    Ravandi, Farhad
    Yilmaz, Musa
    Kadia, Tapan M.
    Thompson, Philip A.
    Huang, Xuelin
    Konopleva, Marina
    Ferrajoli, Alessandra
    Jain, Nitin
    Sasaki, Koji
    Macaron, Walid
    Alvarado, Yesid
    Borthakur, Gautam
    DiNardo, Courtney D.
    Ohanian, Maro
    Kornblau, Steven M.
    Zhao, Min
    Kwari, Monica
    Thankachan, Jennifer
    Loiselle, Christopher
    Delumpa, Ricardo
    Garris, Rebecca
    Kantarjian, Hagop
    BLOOD, 2022, 140 : 8966 - 8968
  • [44] Phase II study of combination of hyperCVAD with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL).
    Jabbour, Elias
    Kantarjian, Hagop M.
    Thomas, Deborah A.
    Ravandi, Farhad
    Cortes, Jorge E.
    Faderl, Stefan
    Pemmaraju, Naveen
    Kadia, Tapan M.
    Garris, Rebecca S.
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Wierda, William G.
    O'Brien, Susan Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [45] Phase II study of combination of hyperCVAD with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL).
    O'Brien, Susan Mary
    Jabbour, Elias
    Thomas, Deborah A.
    Ravandi, Farhad
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Kadia, Tapan M.
    Garris, Rebecca
    Jeanis, Vicky
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Wierda, William G.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [46] Updated Results from the Phase II Study of Blinatumomab in Combination With Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Haddad, Fadi G.
    Kantarjian, Hagop
    Short, Nicholas J.
    Konopleva, Marina
    Jain, Nitin
    Huang, Xuelin
    Ravandi, Farhad
    Wierda, William
    Borthakur, Gautam
    Sasaki, Koji
    Issa, Ghayas
    Alvarado, Yesid
    Pemmaraju, Naveen
    Garcia-Manero, Guillermo
    Thankachan, Jennifer
    Garris, Rebecca
    Jabbour, Elias
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S204 - S204
  • [47] Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study
    Baek, Dong Won
    Park, Han-Seung
    Sohn, Sang Kyun
    Kim, Dae Young
    Kim, Inho
    Ahn, Jae-Sook
    Do, Young Rok
    Lee, Se Ryeon
    Eom, Hyeon-Seok
    Lee, Won-Sik
    Kim, Sung-Hyun
    Lee, Ho Sup
    Lee, Yoo Jin
    Moon, Joon Ho
    Lee, Je-Hwan
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2023, 38 (05): : 734 - +
  • [48] Combination of hyper-CVAD with imatinib mesylate (STI571) for Philadelphia (Ph)-positive adult acute lymphoblastic leukemia (ALL) or chronic myelogenous leukemia in lymphoid blast phase (CML-LBP).
    Thomas, DA
    Cortes, J
    Giles, FJ
    Faderl, S
    O'Brien, S
    Rios, MB
    Issa, JP
    García-Manero, G
    Koller, C
    Capdeville, R
    Talpaz, M
    Kantarjian, H
    BLOOD, 2001, 98 (11) : 803A - 803A
  • [49] Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
    Daver, Naval
    Thomas, Deborah
    Ravandi, Farhad
    Cortes, Jorge
    Garris, Rebecca
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Kadia, Tapan
    Rytting, Michael
    Konopleva, Marina
    Kantarjian, Hagop
    O'Brien, Susan
    HAEMATOLOGICA, 2015, 100 (05) : 653 - 661
  • [50] Updated results of a phase I/II study of inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia.
    Short, Nicholas James
    Kantarjian, Hagop M.
    O'Brien, Susan Mary
    Ravandi, Farhad
    Thomas, Deborah A.
    Garcia-Manero, Guillermo
    Daver, Naval Guastad
    Borthakur, Gautam
    Jain, Nitin
    Konopleva, Marina
    Sasaki, Koji
    Pemmaraju, Naveen
    Alvarado, Yesid
    Jacob, Jovitta
    Garris, Rebecca
    Thompson, Philip A.
    Cortes, Jorge E.
    Jabbour, Elias
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345